177 related articles for article (PubMed ID: 12371851)
1. Inhibitor scaffolds as new allele specific kinase substrates.
Kraybill BC; Elkin LL; Blethrow JD; Morgan DO; Shokat KM
J Am Chem Soc; 2002 Oct; 124(41):12118-28. PubMed ID: 12371851
[TBL] [Abstract][Full Text] [Related]
2. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.
Liu Y; Shah K; Yang F; Witucki L; Shokat KM
Bioorg Med Chem; 1998 Aug; 6(8):1219-26. PubMed ID: 9784863
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for selective inhibition of Src family kinases by PP1.
Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
[TBL] [Abstract][Full Text] [Related]
4. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
[TBL] [Abstract][Full Text] [Related]
5. Engineering a "methionine clamp" into Src family kinases enhances specificity toward unnatural ATP analogues.
Ulrich SM; Kenski DM; Shokat KM
Biochemistry; 2003 Jul; 42(26):7915-21. PubMed ID: 12834343
[TBL] [Abstract][Full Text] [Related]
6. The pp60c-Src inhibitor PP1 is non-competitive against ATP.
Karni R; Mizrachi S; Reiss-Sklan E; Gazit A; Livnah O; Levitzki A
FEBS Lett; 2003 Feb; 537(1-3):47-52. PubMed ID: 12606029
[TBL] [Abstract][Full Text] [Related]
7. Engineering Src family protein kinases with unnatural nucleotide specificity.
Liu Y; Shah K; Yang F; Witucki L; Shokat KM
Chem Biol; 1998 Feb; 5(2):91-101. PubMed ID: 9495830
[TBL] [Abstract][Full Text] [Related]
8. Conformational restraint is a critical determinant of unnatural nucleotide recognition by protein kinases.
Ulrich SM; Sallee NA; Shokat KM
Bioorg Med Chem Lett; 2002 Nov; 12(21):3223-7. PubMed ID: 12372539
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
10. Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and phospho-acceptor specificity of the wild-type enzyme.
Witucki LA; Huang X; Shah K; Liu Y; Kyin S; Eck MJ; Shokat KM
Chem Biol; 2002 Jan; 9(1):25-33. PubMed ID: 11841936
[TBL] [Abstract][Full Text] [Related]
11. Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic peptides.
Chen G; Porter MD; Bristol JR; Fitzgibbon MJ; Pazhanisamy S
Biochemistry; 2000 Feb; 39(8):2079-87. PubMed ID: 10684658
[TBL] [Abstract][Full Text] [Related]
12. Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position.
Hindley AD; Park S; Wang L; Shah K; Wang Y; Hu X; Shokat KM; Kolch W; Sedivy JM; Yeung KC
FEBS Lett; 2004 Jan; 556(1-3):26-34. PubMed ID: 14706820
[TBL] [Abstract][Full Text] [Related]
13. Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.
Zhou HR; Jia Q; Pestka JJ
Toxicol Sci; 2005 Jun; 85(2):916-26. PubMed ID: 15772366
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
15. Kinetic mechanism and ATP-binding site reactivity of p38gamma MAP kinase.
Fox T; Fitzgibbon MJ; Fleming MA; Hsiao HM; Brummel CL; Su MS
FEBS Lett; 1999 Nov; 461(3):323-8. PubMed ID: 10567720
[TBL] [Abstract][Full Text] [Related]
16. Coordinate signaling by Src and p38 kinases in the induction of cortical cataracts.
Zhou J; Menko AS
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2314-23. PubMed ID: 15223811
[TBL] [Abstract][Full Text] [Related]
17. Oxidant-induced priming of the macrophage involves activation of p38 mitogen-activated protein kinase through an Src-dependent pathway.
Khadaroo RG; Parodo J; Powers KA; Papia G; Marshall JC; Kapus A; Rotstein OD
Surgery; 2003 Aug; 134(2):242-6. PubMed ID: 12947324
[TBL] [Abstract][Full Text] [Related]
18. Chemically reprogramming the phospho-transfer reaction to crosslink protein kinases to their substrates.
Wong AW; Urisman A; Burlingame AL; Shokat KM
Protein Sci; 2019 Mar; 28(3):654-662. PubMed ID: 30636329
[TBL] [Abstract][Full Text] [Related]
19. Catalytic reaction pathway for the mitogen-activated protein kinase ERK2.
Prowse CN; Hagopian JC; Cobb MH; Ahn NG; Lew J
Biochemistry; 2000 May; 39(20):6258-66. PubMed ID: 10821702
[TBL] [Abstract][Full Text] [Related]
20. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
